Research programme: oral cancer therapeutics - Introgen/Colgate-Palmolive
Latest Information Update: 18 Feb 2010
At a glance
- Originator Introgen Therapeutics
- Developer Colgate-Palmolive; Introgen Therapeutics
- Mechanism of Action Tumour suppressor gene transcription stimulants; Tumour suppressor protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer